{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:48Z","timestamp":1790806848265,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Laser ablation of the avascular peripheral retina has been the standard method of ROP treatment. Intravitreal anti-VEGF is useful in the management of ROP patients, especially for aggressive posterior ROP. However, ocular and systemic complication after intravitreal bevacizumab was the main concern. This study aimed to investigate the treatment-related ocular and systemic complications of intravitreal bevacizumab (IVB) in patients with retinopathy of prematurity (ROP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This retrospective study included neonates receiving intravitreal injections of bevacizumab (IVB) (0.625\u00a0mg) to treat ROP. Medical records of the patients were evaluated about the ocular complications after receiving IVB from 2012 to 2019. Treatment-related complications (vitreous hemorrhage, glaucoma, cataract, hyphema, corneal abrasion\/opacity, and endophthalmitis), and disease-progression signs including retinal fold or stage 4 or 5 detachment were documented. Any reports of systemic events after injections were also recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>Mean gestational age and birth weight of 441 patients receiving IVB for type-1 ROP were 28\u2009\u00b1\u20092 (22\u201334\u00a0weeks) and 1121\u2009\u00b1\u2009312 (550\u20132700\u00a0g), respectively. The median follow-up after treatment in all patients and patients with complications was 289.43\u2009\u00b1\u2009257\u00a0days (5\u20131899\u00a0days) and 385.89\u2009\u00b1\u2009311.59 (196\u20131192) days, respectively. Out of 865 eyes, 20 eyes (2.31%, 95% Clopper-Pearson Confidence Interval: 1.14\u20133.54%) have been affected by ocular complications. The rates of different complications included progression of retinopathy in 17 eyes (1.96%), cataracts in 2 eyes (0.23%), and vitreous hemorrhage in one eye (0.11%). No cases of endophthalmitis, thromboembolic events, or death occurred in this study. We evaluated the prevalence ratio (PR) on the multiple risk factors to determine the prediction of the complications. The existence of neovascularization of iris has the highest susceptibility to predict the complication (PR\u2009=\u20095.091, P-value 0.014) following by the presence of retinopathy in zone 1 of the infant\u2019s retina (PR\u2009=\u20094.386, P-value\u2009=\u20090.010).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The incidence rate of complications related to Intravitreal bevacizumab injection was low, which was compatible with previous studies. Bevacizumab injection seems well tolerated in most cases of ROP. Iris neovascularization and the presence of retinopathy in zone 1 were associated with a higher occurrence of complications than the absence of these risk factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-020-00276-3","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T19:14:27Z","timestamp":1610392467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors"],"prefix":"10.1186","volume":"7","author":[{"given":"Fatemeh","family":"Bazvand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Riazi-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Mirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khodabande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Khojastheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsar Dastjani","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramak","family":"Roohipourmoallai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooshang","family":"Faghihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin Ebrahimi","family":"Adib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8829-053X","authenticated-orcid":false,"given":"Mohammadreza Mehrabi","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"issue":"4","key":"276_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","volume":"41","author":"ME Hartnett","year":"2014","unstructured":"Hartnett ME. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol. 2014;41(4):925\u201343. https:\/\/doi.org\/10.1016\/j.clp.2014.08.011.","journal-title":"Clin Perinatol"},{"issue":"67","key":"276_CR2","first-page":"46","volume":"21","author":"C Gilbert","year":"2008","unstructured":"Gilbert C, Muhit M. Twenty years of childhood blindness: what have we learnt? Community Eye Health. 2008;21(67):46\u20137.","journal-title":"Community Eye Health"},{"issue":"5","key":"276_CR3","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1542\/peds.2004-1180","volume":"115","author":"C Gilbert","year":"2005","unstructured":"Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115(5):e518\u201325. https:\/\/doi.org\/10.1542\/peds.2004-1180.","journal-title":"Pediatrics"},{"key":"276_CR4","doi-asserted-by":"publisher","unstructured":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1988;106(4):471\u20139. doi: https:\/\/doi.org\/10.1001\/archopht.1988.01060130517027","DOI":"10.1001\/archopht.1988.01060130517027"},{"issue":"7","key":"276_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1007374.","journal-title":"N Engl J Med"},{"issue":"3","key":"276_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","volume":"44","author":"E McLoone","year":"2007","unstructured":"McLoone E, O\u2019Keefe M, McLoone S, et al. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years. J Pediatric Ophthalmol Strabismus. 2007;44(3):170\u20133.","journal-title":"J Pediatric Ophthalmol Strabismus"},{"issue":"11","key":"276_CR7","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327\u201333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"276_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","volume":"2","author":"R Roohipoor","year":"2018","unstructured":"Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retina. 2018;2(9):942\u20138. https:\/\/doi.org\/10.1016\/j.oret.2018.01.017.","journal-title":"Ophthalmol Retina"},{"key":"276_CR9","doi-asserted-by":"publisher","first-page":"CD009734","DOI":"10.1002\/14651858.CD009734.pub3","volume":"1","author":"MJ Sankar","year":"2018","unstructured":"Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;1:CD009734. https:\/\/doi.org\/10.1002\/14651858.CD009734.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"276_CR10","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013;91(1):e74\u20135. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02469.x.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"276_CR11","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/iae.0000000000000535","volume":"35","author":"YR Hong","year":"2015","unstructured":"Hong YR, Kim YH, Kim SY, et al. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina. 2015;35(9):1772\u20137. https:\/\/doi.org\/10.1097\/iae.0000000000000535.","journal-title":"Retina"},{"key":"276_CR12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0057","author":"GE Quinn","year":"2016","unstructured":"Quinn GE, Darlow BA. Concerns for development after bevacizumab treatment of ROP. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2016-0057.","journal-title":"Pediatrics"},{"issue":"2","key":"276_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327-33.e1. https:\/\/doi.org\/10.1016\/j.ajo.2011.07.005.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"276_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaapos.2017.12.005","volume":"22","author":"D Morrison","year":"2018","unstructured":"Morrison D, Shaffer J, Ying GS, et al. Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. J AAPOS. 2018;22(2):128\u201333. https:\/\/doi.org\/10.1016\/j.jaapos.2017.12.005.","journal-title":"J AAPOS"},{"issue":"1","key":"276_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/09286586.2016.1255765","volume":"24","author":"G Binenbaum","year":"2017","unstructured":"Binenbaum G, Tomlinson LA. Postnatal growth and retinopathy of prematurity study: rationale, design, and subject characteristics. Ophthalmic Epidemiol. 2017;24(1):36\u201347. https:\/\/doi.org\/10.1080\/09286586.2016.1255765.","journal-title":"Ophthalmic Epidemiol"},{"issue":"6","key":"276_CR16","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS ONE. 2015;10(6):e0129383. https:\/\/doi.org\/10.1371\/journal.pone.0129383.","journal-title":"PLoS ONE"},{"issue":"8","key":"276_CR17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"276_CR18","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114(12):2179\u201382. https:\/\/doi.org\/10.1016\/j.ophtha.2007.09.012.","journal-title":"Ophthalmology"},{"key":"276_CR19","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10009-1065","author":"C Amiel-Tison","year":"2008","unstructured":"Amiel-Tison C, Gosselin J. From neonatal to fetal neurology: some clues for interpreting fetal findings. Donald School J Ultrasound Obstetrics Gynecol. 2008. https:\/\/doi.org\/10.5005\/jp-journals-10009-1065.","journal-title":"Donald School J Ultrasound Obstetrics Gynecol"},{"issue":"8","key":"276_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaophthalmol.2013.400","volume":"131","author":"C Karaca","year":"2013","unstructured":"Karaca C, Oner AO, Mirza E, et al. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol. 2013;131(8):1099\u2013101. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.400.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"276_CR21","first-page":"355","volume":"109","author":"N O\u2019Keeffe","year":"2016","unstructured":"O\u2019Keeffe N, Murphy J, O\u2019Keefe M, et al. Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Ir Med J. 2016;109(2):355.","journal-title":"Ir Med J"},{"key":"276_CR22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2015-3218.","journal-title":"Pediatrics"},{"issue":"7","key":"276_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/eye.2012.111","volume":"26","author":"BJ Lee","year":"2012","unstructured":"Lee BJ, Kim JH, Heo H, et al. Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye. 2012;26(7):903\u20139. https:\/\/doi.org\/10.1038\/eye.2012.111.","journal-title":"Eye"},{"issue":"4","key":"276_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3109\/08820538.2013.835842","volume":"29","author":"J Chhablani","year":"2014","unstructured":"Chhablani J, Rani PK, Balakrishnan D, et al. Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7. Semin Ophthalmol. 2014;29(4):222\u20135. https:\/\/doi.org\/10.3109\/08820538.2013.835842.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"276_CR25","doi-asserted-by":"publisher","first-page":"e20152005","DOI":"10.1542\/peds.2015-2005","volume":"137","author":"LH Wu","year":"2016","unstructured":"Wu LH, Yang YH, Lin CH, et al. Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity. Pediatrics. 2016;137(2):e20152005. https:\/\/doi.org\/10.1542\/peds.2015-2005.","journal-title":"Pediatrics"},{"key":"276_CR26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1814","author":"G Twitty","year":"2019","unstructured":"Twitty G, Weiss M, Albayram MS, et al. Hypertension and neuroimaging changes after bevacizumab for retinopathy of prematurity. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2019-1814.","journal-title":"Pediatrics"},{"issue":"11","key":"276_CR27","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121(11):2212\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015.","journal-title":"Ophthalmology"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-020-00276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40942-020-00276-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-020-00276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T19:57:38Z","timestamp":1610395058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-020-00276-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1186\/s40942-020-00276-3","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"8 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human subjects were included in this study. The institutional review board of the Tehran University of Medical Science approved the study. The study was conducted according to the tenets of the Declaration of Helsinki. Any procedure was done after providing parents with informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient's parents (that his fundus photographs were used in the Fig. ) for publication of any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}